secwatch / observer
8-K filed June 29, 2023, 7:59 PM ET ticker PCSA CIK 0001533743
other material confidence high sentiment neutral materiality 0.60

Processa increases authorized common shares to 100M; all director nominees elected at annual meeting

Processa Pharmaceuticals, Inc.

item 5.03item 5.07item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Processa Pharmaceuticals, Inc.: Increased authorized shares of common stock from 50,000,000 to 100,000,000 (effective 2023-06-27).

Change
charter amendment
Effective
2023-06-27
Exact text from the filing
Effective June 27, 2023, Processa Pharmaceuticals, Inc. (the “Company” or “us” or “we”) filed an amendment to its Fourth Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the number of authorized shares of common stock from 50,000,000 shares to 100,000,000 shares (the “Amendment”).
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Processa Pharmaceuticals, Inc. shareholders approved Election of all six directors to serve until the next Annual Meeting of Shareholders or until their successors have been duly elected and qualified at the 2023-06-27 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-06-27
Exact text from the filing
1. The election of all six directors to serve until the next Annual Meeting of Shareholders or until their successors have been duly elected and qualified based on the following votes: Shares Name For Against Abstain Broker Non-Votes Justin Yorke 10,850,801 - 879,725 2,477,214 Dr. David Young 9,973,718 - 1,756,808 2,477,214 Khoso Baluch 10,909,404 - 821,122 2,477,214 James Neal 10,899,404 - 831,122 2,477,214 Geraldine Pannu 9,817,229 - 1,913,297 2,477,214 Virgil Thompson 10,226,498 - 1,504,028 2,477,214
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Processa Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of BD & Company, Inc. as the independent registered public accounting firm for 2023 at the 2023-06-27 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-06-27
Exact text from the filing
3. The appointment of BD & Company, Inc. as the independent registered public accounting firm for 2023 was ratified based on the following votes: Shares For Against Abstain Broker Non-Vote 12,862,749 398,544 946,447 -
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Processa Pharmaceuticals, Inc. shareholders approved Amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 shares to 100,000,000 shares at the 2023-06-27 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2023-06-27
Exact text from the filing
2. The amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 shares to 100,000,000 shares. The votes cast were as follows: Shares For Against Abstain Broker Non-Vote 12,430,395 1,736,546 40,799 -
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Processa Pharmaceuticals, Inc. shareholders approved Advisory vote relating to compensation of our named executive officers at the 2023-06-27 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2023-06-27
Exact text from the filing
4. Results of the advisory vote relating to compensation of our named executive officers were as follows: Shares For Against Abstain Broker Non-Vote 9,724,358 1,916,645 89,523 2,477,214
View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Processa Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR
accession 0001493152-23-022920
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.